KRAS and non-small cell lung carcinoma: Moreover, atorvastatin reversed KRAS-mediated gefitinib resistance in NSCLC cells by inhibiting HMG-CoA reductase-dependent disruption of Kras/Raf and Kras/PI3K complexes (Chen et al., 2013).